Summit Therapeutics partners with GSK for cancer drug combination trial

Summit Therapeutics Inc. (NASDAQ: SMMT) announced a clinical trial collaboration with GSK plc (LSE/NYSE: GSK) to evaluate ivonescimab in combination with GSK's investigational B7-H3 antibody drug conjugate risvutatug rezetecan across multiple solid tumor settings, including small cell lung cancer.

The collaboration aims to investigate the combination potential of ivonescimab, Summit's PD-1/VEGF bispecific antibody, with GSK's B7-H3 targeting antibody drug conjugate to determine safety profiles and potential anti-tumor effects. Patient dosing is expected to begin in mid-2026.

Under the agreement terms, Summit will supply ivonescimab for the planned study while GSK will manage day-to-day clinical operations. Each company will maintain rights to their respective products, and the agreement is mutually non-exclusive.

Risvutatug rezetecan, also known as GSK'227, is composed of a fully human anti-B7-H3 monoclonal antibody linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights from Hansoh Pharma, excluding China's mainland, Hong Kong, Macau, and Taiwan. GSK's global phase III trial for the drug in relapsed extensive-stage small cell lung cancer began in August 2025.

Ivonescimab combines immunotherapy through PD-1 blockade with anti-angiogenesis effects from VEGF blocking in a single molecule. Summit submitted a Biologics License Application to the FDA for marketing authorization in the fourth quarter of 2025, based on results from its HARMONi Phase III trial in non-small cell lung cancer.

The drug has been tested in over 4,000 patients in clinical studies globally and over 60,000 patients in commercial settings in China, according to developer Akeso Inc. (HKEX: 9926.HK). Ivonescimab received initial marketing approval in China in May 2024.

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• loanDepot receives NYSE non-compliance notice over stock price
• enVVeno Medical (NVNO) files $100M mixed shelf